Eli Lilly to Bay Merida Biosciences For Up to $2.875 Billion
Dow Jones2026/08/31 11:00By Colin Kellaher
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
Eli Lilly on Monday said privately held Merida is advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, with its lead program in Phase 1 development for Graves' disease and thyroid eye disease.
The Indianapolis company said the deal consideration includes an undisclosed upfront cash payment, along with contingent milestone payments.
The deal is slated to close by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 31, 2026 07:00 ET (11:00 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WESTLAKE CORP <WLK.N>: KEYBANC INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $92
RPM INTERNATIONAL INC <RPM.N>: KEYBANC INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $123
PPG INDUSTRIES, INC. : KEYBANC INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $133
Crypto prices
More
